Marker Therapeutics, Inc.
MRKR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001094038
No open-market purchases or sales by Marker Therapeutics, Inc. insiders were filed in the last 90 days; 35 institutions reported holding it in 13F filings for Q2 2026, worth $5.84M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Marker Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Marker Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Elms Steve | Director | 325,370Indirect | Nov 19, 2025 | 1 |
| Eansor Norman David | Director | 7,142Indirect | Nov 19, 2025 | 1 |
| Knobil Katharine | Director | – | Nov 19, 2025 | 1 |
| Vera Juan | Chief Executive Officer | 2,671,845 | Nov 4, 2025 | 1 |
| Corzo Kathryn Penkus | Director | – | Nov 4, 2025 | 1 |
| Sandell Scott D | 10% Owner | 1,625,678 | Dec 23, 2024 | 0 |
| Baskett Forest | 10% Owner | 1,625,678 | Dec 23, 2024 | 0 |
| Walker Paul Edward | 10% Owner | 1,625,678 | Dec 23, 2024 | 0 |
| Florence Anthony A. Jr. | 10% Owner | 1,625,678 | Dec 23, 2024 | 0 |
| Behbahani Ali | 10% Owner | 1,625,678 | Dec 23, 2024 | 0 |
| Makhzoumi Mohamad | 10% Owner | 1,625,678 | Dec 23, 2024 | 0 |
| New Enterprise Associates 16, L.P. | 10% Owner | 1,625,678 | Dec 23, 2024 | 0 |
| NEA Partners 16, L.P. | 10% Owner | 1,625,678 | Dec 23, 2024 | 0 |
| Nea 16 GP, LLC | 10% Owner | 1,625,678 | Dec 23, 2024 | 0 |
| Chang Carmen | 10% Owner | 1,625,678 | Dec 23, 2024 | 0 |
| Wilson John Robert | Director | – | Jun 8, 2023 | 0 |
| Loiacono Michael | Chief Accounting Officer | – | Mar 1, 2023 | 0 |
| Hoang Tsvetelina P | VP, Research and Development | – | Mar 1, 2023 | 0 |
| Koneru Mythili | Chief Medical Officer | – | Mar 1, 2023 | 0 |
| Agopyan Nadia | SVP, Regulatory Affairs | – | Mar 1, 2023 | 0 |
| Szymanska Anna | Vice President, Quality | – | Mar 1, 2023 | 0 |
| Laskow-Pooley David | Director | – | May 26, 2022 | 0 |
| Hoang Peter L. | President and CEO | 483,286 | Mar 28, 2022 | 0 |
| Kim Anthony H. | Chief Financial Officer | 114,436 | Mar 28, 2022 | 0 |
| Garrett Gerald | Vice President, Clinical Ops. | – | Feb 22, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 26, 2024 (view filing) | Dec 23 | 3 days | Elms SteveDirector | PPurchase | +11.1K | $3.20 | +$35.5K | +3.5%325.4K after | |
| Dec 23, 2024 (view filing)4:40 PM ET | Dec 23 | Same day | Sandell Scott D and 9 others10% Owner | PPurchase | +554.3K | $3.20 | +$1.77M | +51.7%1.63M after | |
| Jun 8, 2023 (view filing) | Mar 16, 2021 | 814 daysLate | Eansor Norman DavidDirector | PPurchase | +14.3K | $17.50 | +$250.0K | +588.3%16.7K after |